Document is current
Any future updates will be listed below
-
Authors
Kawasaki, Aya
Namba, Natsumi
Sada, Ken-ei
Hirano, Fumio
Kobayashi, Shigeto
Nagasaka, Kenji
Sugihara, Takahiko
Ono, Nobuyuki
Fujimoto, Takashi
Kusaoi, Makio
Tamura, Naoto
Yamagata, Kunihiro
Sumida, Takayuki
Hashimoto, Hiroshi
Ozaki, Shoichi
Makino, Hirofumi
Arimura, Yoshihiro
Harigai, Masayoshi
Tsuchiya, Naoyuki https://orcid.org/0000-0002-6776-5580
-
Funding
Funding for this research was provided by:
Japan Agency for Medical Research and Development (19ek0109360h002)
Bristol-Myers Squibb
Japan College of Rheumatology
Japan Rheumatism Association
- License Information
-
More Information
Article History
Received: 23 June 2020
Accepted: 6 October 2020
First Online: 16 October 2020
Ethics approval and consent to participate
: This study was reviewed and approved by the Ethics Committees of University of Tsukuba Faculty of Medicine (No. 180, 227, 268), Tokyo Women’s Medical University, Tokyo Medical and Dental University, and all other institutes participating in this study, and was conducted in accordance with the principles of the Declaration of Helsinki. Informed consent was obtained from all participants.
: Not applicable
: Dr. Sada has received speaker’s honoraria from Chugai Pharmaceutical Co. Ltd.Dr. Hirano has received research grants and/or speaker’s honoraria from Chugai Pharmaceutical Co. Ltd., Ono Pharmaceuticals, CSL Behring, Towa Pharmaceutical Co. Ltd., Abbvie Japan Co. Ltd., Japan Blood Products Organization, Ayumi Pharmaceutical Co., Nippon Kayaku Co. Ltd., Astellas Pharma Inc., Sumitomo Dainippon Pharma, and UCB Japan.Dr. Nagasaka has received speaker’s honoraria from Bristol-Myers Squibb Co. Ltd., Chugai Pharmaceutical Co. Ltd., and Teijin Pharma Ltd.Dr. Makino is a consultant for AbbVie, Teijin, and Boehringer-Ingelheim.Dr. Harigai has received research grants and/or honoraria from AbbVie Japan Co. Ltd., Bristol-Myers Squibb K.K., Chugai Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Co., Ono Pharmaceutical Co. Ltd., Taisho Toyama Pharmaceutical Co. Ltd., Ayumi Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Teijin Pharma Ltd., and Pfizer Japan Inc. Dr. Harigai serves as a consultant for Bristol-Myers Squibb K.K., Chugai Pharmaceutical Co. Ltd., CIMIC Co. Ltd., Kissei Pharmaceutical Co. Ltd., Ono Pharmaceutical Co. Ltd., and Pfizer Japan Inc.Dr. Tsuchiya has received research fund from H.U. Group Research Institute G.K. for a collaborative research unrelated to this study, and research grants from Bristol-Myers Squibb, 2015 Japan College of Rheumatology Award from Japan College of Rheumatology, 2017 Novartis Rheumatology Award from Japan Rheumatism Association with research funding, and speaker’s honoraria from Teijin.Other authors declare no potential conflict of interest.
